Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

CAR-T

Therapeutic area intelligence for CAR-T with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
8
Catalysts
0
Companies
1

Companies

Eli Lilly →

Assets

Emerging →
KLN-1010 →
Obecabtagene →
Phase →
Pomalidomide →
Universal →

Recent signals(8)

ClinicalAugust 4, 2026

Study on NGS Testing to Monitor B-ALL Relapse Post CART Therapy in Children

A study is evaluating the effectiveness of NGS testing and monitoring of B-cell recovery in children with B-ALL post CART therapy.

CompetitiveJuly 21, 2026

Lilly to acquire Kelonia Therapeutics for in vivo CAR-T cell therapy advancement

Lilly is acquiring Kelonia Therapeutics to enhance its portfolio in in vivo CAR-T cell therapies, particularly targeting relapsed/refractory multiple myeloma.

ClinicalJuly 2, 2026

Phase 1 Study of TROP2 CAR-NK Cells for Platinum Resistant Ovarian Cancer

A Phase 1 trial is investigating TROP2 CAR-engineered NK cells delivered intraperitoneally for patients with platinum-resistant ovarian cancer.

ClinicalJune 25, 2026

Obecabtagene Autoleucel Trial for MRD-Negative B-cell ALL Initiated

A clinical trial is underway to evaluate the efficacy of obecabtagene autoleucel in patients with B-cell acute lymphoblastic leukemia in complete remission.

ClinicalJune 25, 2026

Phase 1 Study of PSMA/CD70 Bi-specific CAR-T Cell Therapy Initiated

A Phase 1 clinical trial is underway to evaluate the safety and efficacy of PSMA/CD70 bi-specific CAR-T cell therapy.

ClinicalJune 25, 2026

JNJ-68284528 (cilta-cel) vs Standard Therapy in Multiple Myeloma Study Initiated

A study is underway comparing the efficacy of JNJ-68284528 (cilta-cel) against standard therapies in multiple myeloma.

ClinicalJune 25, 2026

Universal CAR-T Cells Show Promise in Multiple Myeloma Study

A clinical trial is underway to evaluate universal CAR T cells for treating multiple myeloma, focusing on safety and efficacy.

CompetitiveJune 21, 2026

Emerging Trends in CAR-T Immunotherapy Research for Breast Cancer Identified

A bibliometric analysis reveals significant research activity in CAR-T immunotherapy for breast cancer, highlighting key contributors and emerging hotspots.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.